Rituximab as a first step in tackling transformation
A partir de données portant sur 8 116 patients européens atteints d'un lymphome folliculaire diagnostiqué entre 1997 et 2013, cette étude rétrospective analyse l'effet du rituximab sur le risque de transformation histologique de la maladie et sur la survie des patients (durée médiane de suivi : 87 mois)
The earliest description of follicular lymphoma transformation dates back to the 1940s, when a sequential biopsy from a patient was identified to have a “less differentiated appearance”.1 More than 70 years on, we still do not have a uniform definition of transformation, with the widely accepted dogma of confirmation through a repeat biopsy not followed universally for wide-ranging reasons. As a consequence, the true incidence of bona-fide histological transformation and how it is affected by modern treatment approaches are unknown.
The Lancet Haematology , commentaire, 2017